Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Plausible Mechanism Draft Guidance
-
ACMG Response to RFI on Gene Therapies Access for Rare Diseases
-
ACMG Comment to NCD on Germline Editing and Impact on People with Disabilities
-
Group Sign-on Letter to Congress Opposing the Preserving Employee Wellness Programs Act (HR 1313)
-
ACMG Comments to EEOC Concerning Proposed Rule Related to the Genetic Information Nondiscrimination Act (GINA)
-
ACMG Comments to OHRP Concerning Proposed Revisions to the Common Rule
-
ACMG Comments to EEOC Concerning Regulations Under the Americans with Disabilities Act (ADA)